RxDoctor Payments Data

Erin Mullaney, MD

Allergy & Immunology · Greenville, SCNPI 1285924662

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for allergy & immunology clinicians in SC, where the typical reported total is $7,297.

$1,696in general payments, 2019–2025

Across 82 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$182
  • AstraZeneca$159
  • CSL Behring$149
  • GSK$145
  • Biocryst US Sales Co., LLC$117
  • Takeda Pharmaceuticals U.S.A., Inc.$105
  • plus $840 from 22 others

What the payments were for

  • Food & beverage$1,696100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,696 in reported general payments places this provider in the 20th percentile of 46 allergy & immunology providers in South Carolina.

See all allergy & immunology providers in South Carolina

Medicare billing

Part B allowed, 2024
$10,558
Medicare patients
82
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab47$147,315
Epinephrine34$8,101
Cromolyn Sodium27$4,492
Mometasone Furoate12$1,454
Azelastine Hcl45$1,405
Montelukast Sodium26$374
Fluticasone Propionate20$338
Albuterol Sulfate HfaAlbuterol Sulfate12$325
Doxepin Hcl12$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAEpinephrine$36$8,10134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 46 allergy & immunology providers in South Carolina.

Other allergy & immunology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →